Phase 2 Efficacy and Safety of Riliprubart, a C1s-Complement Inhibitor, in Chronic Inflammatory Demyelinating Polyneuropathy (S16.009)
Luís Querol, Miguel Alonso‐Alonso, Erik Wallstroem, Richard AC Hughes et al.
Citations
3 citations
Journal
Neurology
Topics
Peripheral Neuropathies and Disorders
Field-Weighted Citation Impact (FWCI)
4.17
article
Phase 2 Efficacy and Safety of Riliprubart, a C1s-Complement Inhibitor, in Chronic Inflammatory Demyelinating Polyneuropathy (S16.009)
Luís Querol, Miguel Alonso‐Alonso, Erik Wallstroem, Richard AC Hughes, Nazem Atassi, Hans‐Peter Hartung, Xiaodong Luo, Richard A. Lewis, Pieter A. van Doorn, Kristen Auwarter
article en
3 citations
Abstract
No abstract available for this paper.
Publication Tag
NeurologyVol. 104(7_Supplement_1)
Institutions
Cedars-Sinai Medical Center (US), The University of Sydney (AU), Hospital de Sant Pau (ES), Erasmus MC (NL), Centre for Biomedical Network Research on Rare Diseases (ES), Sanofi (United States) (US), Centro de Investigación Biomédica en Red (ES), National Hospital for Neurology and Neurosurgery (GB), Heinrich Heine University Düsseldorf (DE), University College London (GB), Palacký University Olomouc (CZ), Medical University of Vienna (AT)